Tricida, Inc. (NASDAQ: TCDA) announced today the top-line results from its VALOR-CKD renal outcomes clinical trial, designed to evaluate veverimer’s ability to slow CKD progression in patients with metabolic acidosis and chronic kidney disease (CKD).
Primary Endpoint Analysis
The VALOR-CKD trial did not meet its primary endpoint, which was defined as the time to the first occurrence of any event in the composite endpoint of renal death, end-stage renal disease (ESRD), or a confirmed greater than or equal to 40% reduction in estimated glomerular filtration rate (eGFR), also known as DD40. One hundred forty-nine veverimer-treated patients versus 148 placebo-treated patients experienced a DD40 primary endpoint event, representing a veverimer to placebo hazard ratio of 0.99 [95% CI, 0.78, 1.24; (p=0.898)] over the 26.7 months median duration of treatment.
Tricida will host a conference call and webcast that will include a slide presentation at 8:00 am Eastern Time to discuss the results of the VALOR-CKD clinical trial:
The VALOR-CKD Clinical Trial Results Conference Call | |
Monday, October 24, 2022 | |
8:00 am Eastern Time | |
Webcast: | |
Dial-in: | (800) 715-9871 |
International: | (646) 307-1963 |
Conference ID: | 2832909 |
A replay of the webcast will be available on Tricida’s website approximately two hours following the completion of the call and will be available for up to 90 days.
https://finance.yahoo.com/news/tricida-reports-topline-results-valor-110000893.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.